{"id":63123,"date":"2026-04-14T20:48:32","date_gmt":"2026-04-14T12:48:32","guid":{"rendered":"https:\/\/flcube.com\/?p=63123"},"modified":"2026-04-14T20:48:33","modified_gmt":"2026-04-14T12:48:33","slug":"erasca-exercises-option-to-secure-global-rights-to-pan-ras-molecular-glue-eras-0015-from-joyo-pharmatech","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63123","title":{"rendered":"Erasca Exercises Option to Secure Global Rights to Pan-RAS Molecular Glue ERAS-0015 from Joyo Pharmatech"},"content":{"rendered":"\n<p><strong>Erasca, Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/ERAS:NASDAQ\">NASDAQ: ERAS<\/a>) announced on <strong>March 10, 2026<\/strong>, the exercise of its option to expand its existing license agreement with <strong>Joyo Pharmatech Co., Ltd.<\/strong> to include <strong>Mainland China, Hong Kong SAR, and Macau SAR<\/strong>, securing <strong>worldwide rights<\/strong> to <strong>ERAS-0015<\/strong>, a potential <strong>best-in-class pan-RAS molecular glue<\/strong>. The oral, highly potent compound is designed to inhibit <strong>RAS signaling<\/strong> and is currently being evaluated in the <strong>AURORAS-1 Phase 1 dose escalation trial<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-details\">Transaction Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Specification<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Erasca, Inc. (NASDAQ: ERAS)<\/td><\/tr><tr><td><strong>Partner<\/strong><\/td><td>Joyo Pharmatech Co., Ltd.<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>ERAS-0015 \u2013 oral pan-RAS molecular glue<\/td><\/tr><tr><td><strong>Territory Expansion<\/strong><\/td><td>Mainland China, Hong Kong SAR, Macau SAR<\/td><\/tr><tr><td><strong>Rights Status<\/strong><\/td><td>Worldwide exclusive rights (post-expansion)<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>March 10, 2026<\/td><\/tr><tr><td><strong>Financial Obligation<\/strong><\/td><td>One-time payment to Joyo based on development stage<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-development-status\">Drug Profile &amp; Development Status<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism of Action:<\/strong> Pan-RAS molecular glue designed to inhibit RAS signaling pathway<\/li>\n\n\n\n<li><strong>Administration:<\/strong> Oral formulation with high potency profile<\/li>\n\n\n\n<li><strong>Therapeutic Target:<\/strong> RAS-mutant solid tumors \u2013 addressing one of oncology&#8217;s most challenging target classes<\/li>\n\n\n\n<li><strong>Current Trial:<\/strong> AURORAS-1 Phase 1 dose escalation study in patients with RAS-mutant solid tumors<\/li>\n\n\n\n<li><strong>Data Timeline:<\/strong> Initial Phase 1 monotherapy data expected in first half of 2026<\/li>\n\n\n\n<li><strong>Competitive Positioning:<\/strong> Potential best-in-class profile among emerging RAS-targeted therapies<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-global-development-strategy\">Global Development Strategy<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Unified Approach:<\/strong> Worldwide rights enable coordinated global clinical development and regulatory strategy<\/li>\n\n\n\n<li><strong>Market Access:<\/strong> Comprehensive territorial coverage includes all major pharmaceutical markets globally<\/li>\n\n\n\n<li><strong>Commercial Flexibility:<\/strong> Full control over pricing, distribution, and lifecycle management decisions<\/li>\n\n\n\n<li><strong>Investment Protection:<\/strong> Exclusive global rights maximize return potential on development investment<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-ras-targeted-oncology-landscape\">RAS-Targeted Oncology Landscape<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>High-Unmet Need:<\/strong> RAS mutations occur in approximately 30% of human cancers, historically considered &#8220;undruggable&#8221;<\/li>\n\n\n\n<li><strong>Emerging Opportunity:<\/strong> Recent breakthroughs in RAS targeting have validated the approach, creating premium market positioning<\/li>\n\n\n\n<li><strong>Competitive Differentiation:<\/strong> Molecular glue mechanism offers potential advantages over direct RAS inhibitors in overcoming resistance mechanisms<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-framework\">Financial Framework<\/h2>\n\n\n\n<p>The expanded license requires Erasca to make a <strong>one-time payment<\/strong> to Joyo Pharmatech, with the amount determined by the <strong>stage of Joyo&#8217;s development program<\/strong> at the time of option exercise. Specific financial terms were not disclosed, but the structure aligns with typical biopharmaceutical licensing arrangements for preclinical to early clinical assets.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global RAS Market:<\/strong> Potential multi-billion dollar opportunity across multiple solid tumor indications including pancreatic, colorectal, and non-small cell lung cancer<\/li>\n\n\n\n<li><strong>China Significance:<\/strong> Inclusion of Mainland China represents access to the world&#8217;s second-largest pharmaceutical market with high prevalence of RAS-mutant cancers<\/li>\n\n\n\n<li><strong>Development Timeline:<\/strong> Phase 1 data readout in H1 2026 will be critical inflection point for valuation and partnership opportunities<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-next-steps\">Next Steps<\/h2>\n\n\n\n<p>With global rights secured, Erasca can now pursue an integrated worldwide development strategy, potentially accelerating clinical timelines through multi-regional trial designs and streamlined regulatory submissions across major markets.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory pathways, and commercial expectations for ERAS-0015. Actual results may differ due to risks inherent in drug development, including clinical trial outcomes, regulatory approvals, competitive dynamics, and market acceptance.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Erasca, Inc. (NASDAQ: ERAS) announced on March 10, 2026, the exercise of its option to&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[772,3743,1499],"class_list":["post-63123","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-erasca","tag-joyo-pharma","tag-nasdaq-eras"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Erasca Exercises Option to Secure Global Rights to Pan-RAS Molecular Glue ERAS-0015 from Joyo Pharmatech - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Erasca, Inc. (NASDAQ: ERAS) announced on March 10, 2026, the exercise of its option to expand its existing license agreement with Joyo Pharmatech Co., Ltd. to include Mainland China, Hong Kong SAR, and Macau SAR, securing worldwide rights to ERAS-0015, a potential best-in-class pan-RAS molecular glue. The oral, highly potent compound is designed to inhibit RAS signaling and is currently being evaluated in the AURORAS-1 Phase 1 dose escalation trial.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63123\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Erasca Exercises Option to Secure Global Rights to Pan-RAS Molecular Glue ERAS-0015 from Joyo Pharmatech\" \/>\n<meta property=\"og:description\" content=\"Erasca, Inc. (NASDAQ: ERAS) announced on March 10, 2026, the exercise of its option to expand its existing license agreement with Joyo Pharmatech Co., Ltd. to include Mainland China, Hong Kong SAR, and Macau SAR, securing worldwide rights to ERAS-0015, a potential best-in-class pan-RAS molecular glue. The oral, highly potent compound is designed to inhibit RAS signaling and is currently being evaluated in the AURORAS-1 Phase 1 dose escalation trial.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63123\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-14T12:48:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-14T12:48:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63123#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63123\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Erasca Exercises Option to Secure Global Rights to Pan-RAS Molecular Glue ERAS-0015 from Joyo Pharmatech\",\"datePublished\":\"2026-04-14T12:48:32+00:00\",\"dateModified\":\"2026-04-14T12:48:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63123\"},\"wordCount\":486,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Erasca\",\"Joyo Pharma\",\"NASDAQ: ERAS\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63123#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63123\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63123\",\"name\":\"Erasca Exercises Option to Secure Global Rights to Pan-RAS Molecular Glue ERAS-0015 from Joyo Pharmatech - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-14T12:48:32+00:00\",\"dateModified\":\"2026-04-14T12:48:33+00:00\",\"description\":\"Erasca, Inc. (NASDAQ: ERAS) announced on March 10, 2026, the exercise of its option to expand its existing license agreement with Joyo Pharmatech Co., Ltd. to include Mainland China, Hong Kong SAR, and Macau SAR, securing worldwide rights to ERAS-0015, a potential best-in-class pan-RAS molecular glue. The oral, highly potent compound is designed to inhibit RAS signaling and is currently being evaluated in the AURORAS-1 Phase 1 dose escalation trial.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63123#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63123\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63123#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Erasca Exercises Option to Secure Global Rights to Pan-RAS Molecular Glue ERAS-0015 from Joyo Pharmatech\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Erasca Exercises Option to Secure Global Rights to Pan-RAS Molecular Glue ERAS-0015 from Joyo Pharmatech - Insight, China&#039;s Pharmaceutical Industry","description":"Erasca, Inc. (NASDAQ: ERAS) announced on March 10, 2026, the exercise of its option to expand its existing license agreement with Joyo Pharmatech Co., Ltd. to include Mainland China, Hong Kong SAR, and Macau SAR, securing worldwide rights to ERAS-0015, a potential best-in-class pan-RAS molecular glue. The oral, highly potent compound is designed to inhibit RAS signaling and is currently being evaluated in the AURORAS-1 Phase 1 dose escalation trial.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63123","og_locale":"en_US","og_type":"article","og_title":"Erasca Exercises Option to Secure Global Rights to Pan-RAS Molecular Glue ERAS-0015 from Joyo Pharmatech","og_description":"Erasca, Inc. (NASDAQ: ERAS) announced on March 10, 2026, the exercise of its option to expand its existing license agreement with Joyo Pharmatech Co., Ltd. to include Mainland China, Hong Kong SAR, and Macau SAR, securing worldwide rights to ERAS-0015, a potential best-in-class pan-RAS molecular glue. The oral, highly potent compound is designed to inhibit RAS signaling and is currently being evaluated in the AURORAS-1 Phase 1 dose escalation trial.","og_url":"https:\/\/flcube.com\/?p=63123","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-14T12:48:32+00:00","article_modified_time":"2026-04-14T12:48:33+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63123#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63123"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Erasca Exercises Option to Secure Global Rights to Pan-RAS Molecular Glue ERAS-0015 from Joyo Pharmatech","datePublished":"2026-04-14T12:48:32+00:00","dateModified":"2026-04-14T12:48:33+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63123"},"wordCount":486,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Erasca","Joyo Pharma","NASDAQ: ERAS"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63123#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63123","url":"https:\/\/flcube.com\/?p=63123","name":"Erasca Exercises Option to Secure Global Rights to Pan-RAS Molecular Glue ERAS-0015 from Joyo Pharmatech - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-14T12:48:32+00:00","dateModified":"2026-04-14T12:48:33+00:00","description":"Erasca, Inc. (NASDAQ: ERAS) announced on March 10, 2026, the exercise of its option to expand its existing license agreement with Joyo Pharmatech Co., Ltd. to include Mainland China, Hong Kong SAR, and Macau SAR, securing worldwide rights to ERAS-0015, a potential best-in-class pan-RAS molecular glue. The oral, highly potent compound is designed to inhibit RAS signaling and is currently being evaluated in the AURORAS-1 Phase 1 dose escalation trial.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63123#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63123"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63123#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Erasca Exercises Option to Secure Global Rights to Pan-RAS Molecular Glue ERAS-0015 from Joyo Pharmatech"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63123","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63123"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63123\/revisions"}],"predecessor-version":[{"id":63124,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63123\/revisions\/63124"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63123"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63123"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63123"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}